Cargando…

Drug-drug interactions with direct-acting antivirals — less is more

Detalles Bibliográficos
Autor principal:	Wong, Grace Lai-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820199/ https://www.ncbi.nlm.nih.gov/pubmed/33317241 http://dx.doi.org/10.3350/cmh.2020.0278

Ejemplares similares

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
por: Smolders, E. J., et al.
Publicado: (2016)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
por: Gao, Lu-Hua, et al.
Publicado: (2021)

Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C
por: Kuo, Meng-Hsuan, et al.
Publicado: (2020)

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis
por: Kwo, Paul, et al.
Publicado: (2020)

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations
por: Cilento, Maria E., et al.
Publicado: (2022)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

Is LESS is actually more?
por: Kekre, Nitin S.
Publicado: (2012)

Less is not always more
por: Batlle Solà, M., et al.
Publicado: (2022)

Broad-Spectrum Antivirals and Antiviral Drug Combinations
por: Oksenych, Valentyn, et al.
Publicado: (2022)

Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents
por: Hong, Jenny, et al.
Publicado: (2020)

When more is less: Emergent suppressive interactions in three-drug combinations
por: Beppler, Casey, et al.
Publicado: (2017)

Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
por: Bellesini, Marta, et al.
Publicado: (2020)

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
por: Poizot-Martin, Isabelle, et al.
Publicado: (2015)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
por: Canonico, Mario Enrico, et al.
Publicado: (2022)

More or Less the Same, but Better
Publicado: (1994)

Fasting for anaesthesia: Less is more!
por: Elliott, Elizabeth M, et al.
Publicado: (2020)

The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?
por: Jeng, Wen-Juei, et al.
Publicado: (2023)

Molecular systems biology at the crossroads: to know less about more, or to know more about less?
por: Latterich, Martin
Publicado: (2005)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Is ‘less or more’ in pediatric cryoablation for atrioventricular nodal reentry tachycardia?
por: Lau, Chu-Pak, et al.
Publicado: (2020)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C
por: Tang, Kuo-Tung, et al.
Publicado: (2022)

THE NARCOTIC DRUGS ACT AND THE PSYCHIATRIST
por: Channabasavanna, S.M.
Publicado: (1986)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019)

Viral Bronchiolitis in Children: Less is More
por: Jerath, Nameet
Publicado: (2021)

Can Less be More in Intensive Care?
por: Kapadia, Farhad N., et al.
Publicado: (2017)

Is it true that less is more in thoracic surgery?
por: Chen-Yoshikawa, Toyofumi F.
Publicado: (2022)

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
por: Hsu, Jui-Ting, et al.
Publicado: (2022)

The Drug Titration Paradox: Correlation of More Drug With Less Effect in Clinical Data
por: Schnider, Thomas W., et al.
Publicado: (2021)

Gerosuppressant Metformin: less is more
por: Menendez, Javier A., et al.
Publicado: (2011)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
por: Adinolfi, Luigi Elio, et al.
Publicado: (2018)

Marine Drugs Acting as Autophagy Modulators
por: Dyshlovoy, Sergey A., et al.
Publicado: (2020)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h2n4e7b26d6q32k5m297oksnjd